KalVista Pharmaceuticals, Inc. (KALV)

NASDAQ: KALV · Real-Time Price · USD
15.51
-0.48 (-3.00%)
At close: Jul 10, 2025, 4:00 PM
15.02
-0.49 (-3.16%)
Pre-market: Jul 11, 2025, 7:35 AM EDT
-3.00%
Market Cap 771.81M
Revenue (ttm) n/a
Net Income (ttm) -183.44M
Shares Out 49.76M
EPS (ttm) -3.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,008,595
Open 16.00
Previous Close 15.99
Day's Range 15.08 - 16.32
52-Week Range 7.30 - 16.32
Beta -0.04
Analysts Strong Buy
Price Target 26.29 (+69.5%)
Earnings Date Jul 10, 2025

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID f... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Benjamin Palleiko
Employees 150
Stock Exchange NASDAQ
Ticker Symbol KALV
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price target is $26.29, which is an increase of 69.50% from the latest price.

Price Target
$26.29
(69.50% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended Apr...

1 day ago - Business Wire

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience an...

2 days ago - Seeking Alpha

US FDA approves KalVista Pharma's swelling disorder drug

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.

4 days ago - Reuters

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralst...

4 days ago - Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted five new...

8 days ago - Business Wire

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pend...

15 days ago - Business Wire

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immun...

25 days ago - Business Wire

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' drug for a type of hereditary swelling disorder due to heavy workload and limited resources, the company said on ...

27 days ago - Reuters

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it ...

27 days ago - Business Wire

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and ...

5 weeks ago - Business Wire

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angi...

5 weeks ago - Business Wire

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Jefferies Global Heal...

6 weeks ago - Business Wire

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place...

7 weeks ago - Business Wire

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Science...

2 months ago - Business Wire

KalVista: Poised For Rare Disease Transformation

KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial positi...

3 months ago - Seeking Alpha

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed com...

3 months ago - Business Wire

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham V...

3 months ago - Business Wire

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of seb...

3 months ago - Business Wire

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provide...

4 months ago - Business Wire

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization ...

4 months ago - Business Wire

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioe...

4 months ago - Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following inv...

4 months ago - Business Wire

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of ...

4 months ago - Business Wire

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat ...

5 months ago - Business Wire

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralst...

6 months ago - Business Wire